Jpmorgan Chase & CO Bio Line Rx Ltd. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BLRX
# of Institutions
38Shares Held
4.34MCall Options Held
49.9KPut Options Held
122K-
Alyeska Investment Group, L.P. Chicago, IL1.95MShares$820,4130.01% of portfolio
-
Cvi Holdings, LLC Wilmington, DE816KShares$342,5864.05% of portfolio
-
Envestnet Asset Management Inc214KShares$89,8090.0% of portfolio
-
Values First Advisors, Inc.198KShares$82,9560.06% of portfolio
-
Atria Investments LLC Charlotte, NC134KShares$56,2690.0% of portfolio
About BioLineRx Ltd.
- Ticker BLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,524,500
- Market Cap $25.8M
- Description
- BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...